Financial reports
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
15 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
10-Q
2021 Q2
Quarterly report
5 Aug 21
10-Q
2021 Q1
Quarterly report
11 May 21
10-K
2020 FY
Annual report
4 Mar 21
10-Q
2020 Q3
Quarterly report
12 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
Current reports
8-K
Termination of a Material Definitive Agreement
2 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
1 Mar 23
8-K
Departure of Directors or Certain Officers
27 Feb 23
8-K
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
7 Feb 23
8-K
Departure of Directors or Certain Officers
9 Jan 23
8-K
Entry into a Material Definitive Agreement
15 Nov 22
8-K
Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
14 Nov 22
8-K
Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
11 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 22
8-K
Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene
8 Jun 22
Registration and prospectus
15-12G
Securities registration termination
13 Mar 23
POS AM
Prospectus update (post-effective amendment)
6 Mar 23
POS AM
Prospectus update (post-effective amendment)
6 Mar 23
POS AM
Prospectus update (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
Proxies
DEFA14A
Additional proxy soliciting materials
22 Feb 23
DFAN14A
Additional proxy materials by non-management
16 Feb 23
DEFA14A
Additional proxy soliciting materials
7 Feb 23
DFAN14A
Additional proxy materials by non-management
6 Feb 23
DEFM14A
Proxy related to merger
4 Jan 23
PREM14A
Preliminary proxy related to merger
21 Dec 22
DFAN14A
Additional proxy materials by non-management
20 Dec 22
DFAN14A
Additional proxy materials by non-management
7 Dec 22
DEFA14A
Additional proxy soliciting materials
14 Nov 22
DEFA14A
Additional proxy soliciting materials
14 Nov 22
Other
CT ORDER
Confidential treatment order
11 Jul 23
EFFECT
Notice of effectiveness
10 Mar 23
EFFECT
Notice of effectiveness
10 Mar 23
EFFECT
Notice of effectiveness
10 Mar 23
EFFECT
Notice of effectiveness
24 Aug 21
CORRESP
Correspondence with SEC
19 Aug 21
UPLOAD
Letter from SEC
18 Aug 21
EFFECT
Notice of effectiveness
26 Jan 21
CORRESP
Correspondence with SEC
21 Jan 21
UPLOAD
Letter from SEC
15 Jan 21